180 related articles for article (PubMed ID: 37445886)
21. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.
Castillo RR; Lozano D; González B; Manzano M; Izquierdo-Barba I; Vallet-Regí M
Expert Opin Drug Deliv; 2019 Apr; 16(4):415-439. PubMed ID: 30897978
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
24. Targeted Delivery of Metformin Against Lung Cancer Cells Via Hyaluronan-Modified Mesoporous Silica Nanoparticles.
Zhang F; Liu W; Long Y; Peng H
Appl Biochem Biotechnol; 2023 Jul; 195(7):4067-4083. PubMed ID: 36652095
[TBL] [Abstract][Full Text] [Related]
25. Carboxyl-functionalized mesoporous silica nanoparticles for the controlled delivery of poorly water-soluble non-steroidal anti-inflammatory drugs.
Gou K; Wang Y; Guo X; Wang Y; Bian Y; Zhao H; Guo Y; Pang Y; Xie L; Li S; Li H
Acta Biomater; 2021 Oct; 134():576-592. PubMed ID: 34280558
[TBL] [Abstract][Full Text] [Related]
26. Physical Characterization and Safety Evaluation of Folic Acid-conjugated Mesoporous Silica Nanoparticles Loaded with Rhodojaponin III.
Yang Q; Zhao C; Yang J; Zhao J; Feng Y; Liu M; Zhang J
Curr Drug Deliv; 2023; 20(10):1559-1568. PubMed ID: 36366851
[TBL] [Abstract][Full Text] [Related]
27. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Liu G; Zheng D; Tian X
Int J Pharm; 2013 Mar; 445(1-2):12-9. PubMed ID: 23384728
[TBL] [Abstract][Full Text] [Related]
29. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
[TBL] [Abstract][Full Text] [Related]
30. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
31. Morin Hydrate Encapsulation and Release from Mesoporous Silica Nanoparticles for Melanoma Therapy.
Cunha C; Marinheiro D; Ferreira BJML; Oliveira H; Daniel-da-Silva AL
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375331
[TBL] [Abstract][Full Text] [Related]
32. Co-Delivery of Silymarin and Metformin Dual-Loaded in Mesoporous Silica Nanoparticles Synergistically Sensitizes Breast Cancer Cell Line to Mitoxantrone Chemotherapy.
Rezaei Harandi Z; Heidari R; Reiisi S
IEEE Trans Nanobioscience; 2023 Oct; 22(4):872-880. PubMed ID: 37022888
[TBL] [Abstract][Full Text] [Related]
33. Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy.
Lohiya G; Katti DS
Carbohydr Polym; 2022 Feb; 277():118822. PubMed ID: 34893239
[TBL] [Abstract][Full Text] [Related]
34. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J
Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452
[TBL] [Abstract][Full Text] [Related]
35. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Gurka MK; Pender D; Chuong P; Fouts BL; Sobelov A; McNally MW; Mezera M; Woo SY; McNally LR
J Control Release; 2016 Jun; 231():60-7. PubMed ID: 26763377
[TBL] [Abstract][Full Text] [Related]
36. Multistage pH-responsive mesoporous silica nanohybrids with charge reversal and intracellular release for efficient anticancer drug delivery.
Yuan X; Peng S; Lin W; Wang J; Zhang L
J Colloid Interface Sci; 2019 Nov; 555():82-93. PubMed ID: 31377647
[TBL] [Abstract][Full Text] [Related]
37. Facile Synthesis of Three Types of Mesoporous Silica Microspheres as Drug Delivery Carriers and their Sustained-Release Properties.
Zhu Y; Wang B; Chen J; He J; Qiu X
Curr Drug Deliv; 2023; 20(9):1337-1350. PubMed ID: 35713141
[TBL] [Abstract][Full Text] [Related]
38. Dual response to pH and chiral microenvironments for the release of a flurbiprofen-loaded chiral self-assembled mesoporous silica drug delivery system.
Wu L; Gou K; Guo X; Guo Y; Chen M; Hou J; Li S; Li H
Colloids Surf B Biointerfaces; 2021 Mar; 199():111501. PubMed ID: 33338882
[TBL] [Abstract][Full Text] [Related]
39. Smart MSN-Drug-Delivery System for Tumor Cell Targeting and Tumor Microenvironment Release.
Dong JH; Ma Y; Li R; Zhang WT; Zhang MQ; Meng FN; Ding K; Jiang HT; Gong YK
ACS Appl Mater Interfaces; 2021 Sep; 13(36):42522-42532. PubMed ID: 34463488
[TBL] [Abstract][Full Text] [Related]
40. Gold-capped mesoporous silica nanoparticles as an excellent enzyme-responsive nanocarrier for controlled doxorubicin delivery.
Eskandari P; Bigdeli B; Porgham Daryasari M; Baharifar H; Bazri B; Shourian M; Amani A; Sadighi A; Goliaei B; Khoobi M; Saboury AA
J Drug Target; 2019 Dec; 27(10):1084-1093. PubMed ID: 30900473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
